Phase II study of docetaxel-prednisone (DP) in combination with metronomic cyclophosphamide (CTX) and celecoxib (C) as first-line treatment in castration resistant prostate cancer (CRPC) patients (Pts)

被引：0
|
作者：
Fontana, A.
Bocci, G.
Galli, L.
Derosa, L.
Minuti, G.
D'Arcangelo, M.
Santini, D.
Landi, L.
Bursi, S.
Falcone, A.
机构：
[1] ASL6, Livorno, Italy
[2] Univ Pisa, ITT, Pisa, Italy
[3] ASL6, ITT, Livorno, Italy
[4] Univ Campus Bio Med, Rome, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16032
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A randomized, double-blind phase II trial of docetaxel plus prednisone (DP) combined with either AT101 or placebo for the first-line therapy of metastatic castration-resistant prostate cancer (CRPC)
    Sonpavde, G.
    Matveev, V. B.
    Burke, J. M.
    Caton, J. R.
    Fleming, M. T.
    Karlov, P. A.
    Holmlund, J.
    Wood, B. A.
    Brookes, M.
    Leopold, L. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [22] A randomized, double-blind phase II trial of docetaxel plus prednisone (DP) combined with either AT-101 or placebo for the first-line therapy of metastatic castration-resistant prostate cancer (CRPC)
    Sonpavde, G.
    Matveev, V. B.
    Burke, J. M.
    Caton, J. R.
    Fleming, M. T.
    Karlov, P. A.
    Holmlund, J.
    Wood, B. A.
    Brookes, M.
    Leopold, L. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [23] Low-dose metronomic oral cyclophosphamide plus prednisone for castration resistant prostate cancer (CRPC): A retrospective study.
    Martinez Lago, Nieves
    Anido Herranz, Urbano
    Leon Mateos, Luis
    Vieito, Maria
    Varela Ponte, Rafael
    Aguin Losada, Santiago
    Brozos Vazquez, Elena
    Carmona Campos, Marta
    Rodriguez Lopez, Carmela
    Cortegoso Mosquera, Alexandra Sabela
    Candamio Folgar, Sonia
    Lopez Lopez, Rafael
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [24] Metronomic oral cyclophosphamide plus prednisone in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer
    Romualdo Barroso-Sousa
    Leonardo Gomes da Fonseca
    Karla Teixeira Souza
    Ana Carolina Ribeiro Chaves
    Ariel Galapo Kann
    Gilberto de Castro
    Carlos Dzik
    Medical Oncology, 2015, 32
  • [25] Metronomic oral cyclophosphamide plus prednisone in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer
    Barroso-Sousa, Romualdo
    da Fonseca, Leonardo Gomes
    Souza, Karla Teixeira
    Ribeiro Chaves, Ana Carolina
    Kann, Ariel Galapo
    de Castro, Gilberto, Jr.
    Dzik, Carlos
    MEDICAL ONCOLOGY, 2015, 32 (01) : 1 - 6
  • [26] Docetaxel Plus Oral Metronomic Cyclophosphamide: A Phase II Study With Pharmacodynamic and Pharmacogenetic Analyses in Castration-Resistant Prostate Cancer Patients
    Derosa, Lisa
    Galli, Luca
    Orlandi, Paola
    Fioravanti, Anna
    Di Desidero, Teresa
    Fontana, Andrea
    Antonuzzo, Andrea
    Biasco, Elisa
    Farnesi, Azzurra
    Marconcini, Riccardo
    Francia, Giulio
    Danesi, Romano
    Falcone, Alfredo
    Bocci, Guido
    CANCER, 2014, 120 (24) : 3923 - 3931
  • [27] A phase I study of sorafenib in association with docetaxel-prednisone in chemonaive metastatic castration-resistant prostate cancer
    Mardjuadi, F.
    Medioni, J.
    Kerger, J.
    Canon, J. L.
    Duck, L.
    Oudard, S.
    Clausse, M.
    D'Hondt, L.
    Moxhon, A.
    Machiels, J. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [28] A phase II study of maintenance therapy with temsirolimus (TEM) after response to first-line docetaxel (TAX) chemotherapy in castration-resistant prostate cancer (CRPC)
    Emmenegger, U.
    Sridhar, S. S.
    Booth, C. M.
    Kerbel, R.
    Berry, S. R.
    Ko, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [29] A phase II study of maintenance therapy with temsirolimus (TEM) after response to first-line docetaxel (TAX) chemotherapy in castration-resistant prostate cancer (CRPC).
    Emmenegger, U.
    Berry, S. R.
    Booth, C. M.
    Sridhar, S. S.
    Winquist, E.
    Bandali, N.
    Chow, A.
    Kerbel, R.
    Ko, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [30] Phase II study of maintenance therapy with temsirolimus (TEM) after response to first-line docetaxel (TAX) chemotherapy in castration-resistant prostate cancer (CRPC)
    Emmenegger, U.
    Berry, S. R.
    Booth, C.
    Sridhar, S. S.
    Winquist, E.
    Bandali, N.
    Chow, A.
    Kerbel, R. S.
    Ko, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
12345